Drug intelligence / Profile preview

GLU-06

Development stage: Discontinued
Lead developer: CV Technologies
Administration: Oral

Overview

GLU-06 was a dietary supplement investigated in an open-label, dose-finding pilot study (NCT01468376) to determine its safety, tolerability, and efficacy in individuals with impaired glucose tolerance. The study, sponsored by Afexa Life Sciences Inc., was terminated in January 2012 after the company was acquired and the new owner decided not to proceed.

Other names: Dietary Supplement : GLU-06

Beyond the preview

Go deeper on GLU-06.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GLU-06.